Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric plaque psoriasis study of guselkumab versus placebo and etanercept
NL-OMON52759Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in plaque psoriasis and psoriasis (4 arms), sponsored by Janssen Pharmaceutical. Started Mar 2019; status: active, not recruiting.
02
Drugs
guselkumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on NL-OMON52759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52759.